Table 5.
Protective efficacy of F. tularensis type A CLC against type A SCHU S4 challenge of mice.
| Number of mice | Immunogen | Challenge dose | Time to euthanasia post-challenge (PC) |
|---|---|---|---|
| 4 | Watera | 100 CFU | 4/4 at 4 days PC |
| 8 | Crude CLC in FAa,b | 100 CFU | 4/4 at 4 days PC |
| 8 | HMS CLC in FAa,c | 100 CFU | 4/4 at 4 days PC |
| 5 | HMS CLC in MPLAa,d | 100 CFU | 4/4 at 4 days PC |
| 5 | HMS CLC in FAe,b | 150 CFU | 3/5 at 1 day PC; 2/5 at 5 days PC |
| 5 | HMS CLC in MPLAe,d | 150 CFU | 4/5 at 4 days PC; 1/5 at 7 days PC |
a
Mice were immunized subcutaneously with 50 μg of CLC twice 6 weeks apart.
b
FA, Freund's Adjuvant, first immunization was with Complete Adjuvant and the second immunization was with Incomplete Adjuvant. Crude CLC was derived from WbtIG191V_P10 cells that had been extracted with 1 M urea and the bacterial cells removed by centrifugation.
c
HMS CLC, semi- purified CLC including the high molecular size surface antigen was concentrated.
d
MPLA, Monophosphoryl lipid A adjuvant.
e
Mice were immunized twice 3 months apart.